Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy
November 10, 2017 8:16 AM ESTChardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $140.00 following phase III Hummingbird data for brexanolone in PPD.
Analyst Gbola Amusa see a read-across from brexanolone in PPD to other vast-market indications, like MDD, Sage... More
Sage Therapeutics (SAGE) PT Raised to $135 at Cowen
November 9, 2017 3:20 PM ESTCowen raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $135.00 (from $90.00) while maintaining a Outperform rating following positive top-line data from the Ph3 HUMMINGBIRD trials of brexanolone in moderate and severe PPD.
Analyst Ritu Baral is optimistic that... More
Sage Therapeutics (SAGE) PT Raised to $105 at Stifel
November 9, 2017 12:43 PM ESTStifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $91.00) while maintaining a Buy rating after the company reported positive top-line data from P3 Hummingbird trials with brexanolone (i.v. formulation) in postpartum depression (PPD).
Analyst Adam Walsh this... More
Sage Therapeutics (SAGE) PT Raised to $123 at Leerink Partners
November 9, 2017 12:13 PM ESTLeerink Partners analyst Paul Matteis raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $123.00 (from $85.00) while maintaining an Outperform rating.
... MoreSage Therapeutics (SAGE) PT Raised to $100 at Needham & Company
November 9, 2017 11:34 AM ESTNeedham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $100.00 (from $86.00) while maintaining a Buy rating after both IV brexanolone Phase 3 trials in moderate and severe postpartum depression (PPD) hit on the primary efficacy endpoint.
Danielle Brill said it... More
Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMO
November 9, 2017 10:12 AM ESTBMO Capital analyst Gary Nachman reiterated an Outperform rating and $80 price target on Sage Therapeutics (NASDAQ: SAGE) hit its most important milestone as a company to date with very positive data for Brexanolone in two Phase 3 studies in post-partum depression.
Nachman said... More
SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary Endpoint
November 9, 2017 6:42 AM ESTSAGE Therapeutics (NASDAQ: SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary Endpoint
... More